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ABSTRACT 
Background The Poly (ADP-ribose) polymerase inhibitor olaparib, acts against cancer cells in people with 
breast cancer pre-disposition gene mutations (BRCAm).  Despite US and EU approval as a therapy for ovarian 
cancer patients with BRCAm, but research into olaparib therapy for breast cancer patients with BRCAm is in its 
infancy.   
Objective As no systematic review has yet been undertaken to synthesise clinical trials looking at olaparib as a 
therapy for breast cancer patients with BRCAm, this systematic review aims to establish the current 
effectiveness of olaparib as a treatment for these patients.  
Method CINAHL, MEDLINE, Royal College of Nursing, Cochrane Library, Joanna Briggs Institute, Centre for 
Reviews and Dissemination, Internurse, Embase, Google Scholar and PubMed databases were searched, 
supplemented by a grey material search, hand searching and cross referencing. Authors independently reviewed 
and graded the studies also using Kmet et al. scoring system.  
Results One long term case study and six clinical trials were included. Heterogeneity prevented statistical meta-
analysis, meaning only narrative synthesis was possible.  The overall clinical benefit of olaparib appears to be 
greater and longer lived in BRCAm carriers compared to BRCAwt, and also when compared to standard 
chemotherapy treatments.       
Conclusion Implications for nursing: nurses working in this field should be aware that the most compelling 
results were found in the subset of patients who harbour a BRCA mutation, meaning that olaparib should be 
regarded as a clinically effective potential therapy for these patients. Larger, longer term trials including 
comparator arms are required to demonstrate benefits including overall survival, adverse effects and quality of 
life.  
PROSPERO CRD42018087832. 
 
Keywords olaparib, BRCA, BRCAm, systematic review, narrative synthesis.   
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1.1 Introduction 
Alterations in the breast cancer (BC) genes, BRCA1 and BRCA2, can lead to autosomal dominant, highly 
penetrant, predisposition to breast and ovarian cancers, with lifetime risks as high as 84% (1). 
BRCA-mutant (BRCAm) breast cancers are more often high grade triple negative breast cancer (TNBC) which 
means they are negative for oestrogen receptor, progesterone receptor, and human epidermal growth factor 
receptor2 [(HER2)], making them much harder to target therapeutically (2).   TNBC has the poorest overall 
survival of all breast cancer subtypes with the highest rates of metastatic disease (2).  Recent studies have 
revealed an emerging therapy using Poly (ADP-ribose) polymerase inhibitors (PARPi), which has had great 
success when treating BRCAm ovarian cancers.  Olaparib is one of several known PARPis and has been in trials 
as a monotherapy, and in combination other standard therapies, and as a maintenance therapy (3,4,5,6)  
Olaparib has been granted approval in the USA, and in the EU to be used as a therapy for ovarian cancer (OC) 
patients with BRCAm, but as yet the research into olaparib therapy for BC patients with BRCAm is in its 
infancy.  
 No systematic review (SR) has been undertaken synthesise the clinical trials looking at olaparib as a therapy for 
BC patients with BRCAm.   
Given olaparib’s success with BRCAm OC, there is a clear need for a SR and synthesis of the trials 
investigating olaparib as a therapy in BRCAm BC patients.  This paper is the first to conduct such a SR and 
draw tentative conclusions and recommendations based on narrative review of the evidence.  
In addition to germline BRCA tumours, BRCA deficiency is observed in somatic BRCAm tumours (7), so  this 
SR will look at all BRCAm patients regardless of  whether the BRCAm was germline or somatic.  
Firstly, we will outline the basic science and clinical applications of BRCAm BC, PARPi, and olaparib. 
 
1.2 Aetiology of BRCAm Breast Cancer    
Mistakes (mutations) in DNA replication, and failures of DNA repair pathways are central to the development 
of cancer (8).   Cancer cells are cells that have acquired malignant properties such as proliferation, invasion, and 
metastasis.  These malignant cells can evade apoptosis (controlled cell death). Many chemotherapies and some 
targeted agents work by creating catastrophic damage to DNA in malignant cells, as to make the cell non-viable 
(8).  
BRCA1 and BRCA2 are genes involved in DNA repair – they are broadly categorised as tumour suppressors 
(9). So if this repair pathway is impaired (e.g. by BRCAm), then these patients are at increased risk of 
developing BC, OC and other cancers (10).  
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1.3 Synthetic Lethality.   
DNA continually sustains damaging mutations under a barrage of environmental and lifestyle assaults like UV 
light, tobacco, toxic products of metabolism, all promoting faulty DNA replication (8).  Various DNA repair 
mechanisms have evolved to repair these mutations to maintain genomic integrity.  A predominant repair 
pathway utilises Poly (ADP-ribose) polymerase (PARP) enzymes (9). 
BRCAm cancer cells have lost both copies of their normal BRCA gene, so they lose normal BRCA repair 
activity, whereas non-tumour cells maintain one functional copy of the BRCA gene (8).   
This deficiency in repair makes BRCAm cancers hypersensitive to DNA damaging treatments such as platinum 
chemotherapy (9) and Poly (ADP-ribose) polymerase inhibitors (PARPi) (11, 12).  With PARP inhibition 
(PARPi), DNA cannot be repaired in BRCAm cancer cells (13).     
Cells with a working BRCA gene can repair any damage to the double helix.  Cells without a functioning BRCA 
gene rely on PARP to repair the damage, so deficiency of one repair pathway alone (PARP or BRCA) has no 
impact on cell viability.  However, if PARP is inhibited in addition to BRCA being mutated, then the loss of 
both BRCA and PARP repair pathways results in cell death. This is a concept called synthetic lethality and leads 
to cell cycle arrest and apoptosis (controlled cell death) in these cancer cells, i.e. PARPi induces synthetic 
lethality in BRCAm tissues (9, 13).  Olaparib is one of the first known PARPi to exploit this synthetic lethality. 
 
1.4 Current Status of Parp Inhibitors  
PARP inhibitors (PARPi)i have been the centre of a great deal of new research into potential new anti-tumour 
agents since the concept of synthetic lethality was introduced, when BRCAm tumour cells showed over 1000 
fold greater sensitivity to PARPi in preclinical models (11,12).   Since then, a great deal of research has been 
done looking at olaparib as a therapy for OC patients with BRCAm (3, 4, and 5). Clinical studies have verified 
anti-tumour activities of PARPi in BRCA mutant OC tumours (3) and in contrast to the limited efficacy of 
PARPi alone, the combination of PARPi with DNA repair defects is often lethal to tumour cells. The clinical 
efficacy of PARPi as single agents has shown only moderate efficacy, except for in BRCAm or BRCA-like 
tumours (14).    
In December 2014, twenty years after the discovery of the BRCA genes, olaparib (the first in human PARPi) 
was approved for treatment of patients with germline BRCA associated OC with three or more prior lines of 
chemotherapy (15).  This approval represents the first ‘personalised’ therapy for OC.  As well as the approval of 
olaparib was the approval of the Myriad Genetics BRCAnalysis  CDz TM test as the  BRCAm diagnostic test to 
identify patients eligible for olparib treatment.  
Comparatively, olaparib as a therapy for BC patients with the same BRCA deficiency, is lagging behind with 
only one phase 3 trial completed to date, and another ongoing.   
 
5 
 
1.5  Olaparib/Lynparza 
Although olaparib therapy has been approved for OC in the USA and the EU, the optimal application of olaparib 
in treatment of BRCAm BC has not yet been determined. 
In 2012, Ledermann et al. (5) published the results of his phase 2 trial on olaparib as a maintenance therapy for 
platinum sensitive OC patients.  They reported that maintenance olaparib significantly improved progression 
free survival (PFS) in a randomized, double-blind, placebo-controlled trial. Of note – there was a subset of 
patients (11%) in Ledermann et al.’s study (5), including patients with BRCAm and BRCAwt whose results 
showed long-term disease control on maintenance olaparib, and progression free survival (PFS) of over 5 years. 
Despite this, the drug failed to induce prolonged overall survival (OS) - 34.9 months versus 31.9 months.  As a 
result of the benefit of PFS not translating into an improvement in OS, the sponsor announced it would abandon 
plans into phase 3three trials of olaparib therapy, so further development was put on hold.  
A year later, the results from Ledermann et al.’s (5) pre-planned analysis of the data based on BRCAm status 
was presented at the 2013 ACSO annual meeting.  Out of 131 patients receiving olaparib (plus 123 patients 
receiving placebo), 56% and 50% of patients had BRCAm or suspected BRCAm.  The pre-planned retrospective 
analysis (done after patients were reassigned by BRCA status after confirmed Myriad testing), revealed that PFS 
was significantly longer in BRCAm patients than BRCA wild type (wt) patients (11.2 months versus 4.3 
months).  These results demonstrated that OC patients with BRCAm might benefit from olaparib therapy – and 
also indicated that olaparib monotherapy was effective against platinum sensitive recurrent OC with BRCAm 
(5) 
This positive result led Astra Zeneca (AZ) to reverse their decision in 2013, and restart the phase 3 clinical trials 
of olaparib.    Additionally, in response to these results, the European Medicines Agency (EMA) also approved 
olaparib as a maintenance therapy on 18th December 2014 for platinum sensitive OC in patients with BRCAm . 
The clinical data from these trials led to olaparib receiving approval by the US food and drug administration 
(FDA) in 2014 for fourth line or maintenance treatment of BRCAm OC (15).  
The approval of olaparib marked PARPi as a success and reactivated research into PARPi inhibitors as a 
therapeutic strategy for all cancers, especially those with BRCAm.  Since that time, there have been two key 
lines of investigation into the concept of PARPi as a treatment – PARPi monotherapy and PARPi combined 
with DNA-damaging chemotherapy.   
On the 19th December, tThe USA granted approval for olaparib monotherapy to be used in patients with 
germline(g) BRCAm or suspected gBRCAm (as detected by Myriad’s FDA-approved test) advanced OC treated 
with three or more prior lines of chemotherapy (16). 
Last year, aAt the 2017 American Society of Clinical Oncology (ASCO) annual meeting, in discussion 
regarding metastatic BC patients harbouring BRCAm, olaparib was shown to be superior to conventional 
chemotherapy - defining a potential novel treatment standard in this high-risk population.   
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1.6 Rationale for tThis Systematic Review 
Olaparib is an emerging treatment with some questions about its efficacy as a treatment for BRCAm used singly 
or in combination.  A systematic review (SR) is necessary to evaluate, compare and contrast scientific studies 
which examine combinations of therapies, dosage regimes, and outcomes including survival, remission or 
otherwise in the existing primary studies.   
Published research has not yet been synthesised.   SRs are useful to medical, nursing and healthcare research as 
it might help inform future study designs concerning sample sizes, hypothesis, decision making and treatment 
options.  By using explicit scientific principles for the inclusion and exclusion of studies, this SR will overcome 
the potential bias associated with non-systematic reviews. 
 
1.7 Aims and Objectives 
This systematic review aims to investigate the current effectiveness of olaparib in patients with BC and a BRCA 
mutation, and to produce and present this information in such a way as to reduce bias or inaccuracies.  This is 
fundamental to the principle of SR synthesis. This review also aims to make clear links between the studies and 
the conclusions and identify any controversies, weaknesses and gaps in the field. 
 
 
2. Methods 
The methods for this SR were made explicit in a protocol (written in accordance with PRISMA–P guidelines), 
and published on PROSPERO (CRD42018087832), which is an international database of prospective SRs 
recording the key features from a review protocol.   
 
PRISMA focuses on the reporting of reviews evaluating RCTs and other types of research (particularly 
evaluations of interventions) (17).  The Preferred Reporting Items for Systematic reviews and Meta-Analyses 
for Protocols 2015 (18) is a reporting guideline for protocols, consisting of a 17-item checklist intended to 
facilitate the preparation and reporting of a robust protocol for the SR (19). 
 
 
2.1 Review Question 
Key questions are commonly formulated according to the ‘PICO’ method, which defines the population (P), the 
intervention (I), the control/comparator (C), and the outcome (O) (20).  Describing the criteria for each of the 
PICO elements enables the researcher to understand what is relevant, and what is not relevant, to the specific 
question being asked (21).  The population for studies in this review is patients over the age of 18 with BC and 
BRCAm. Gender is not a variable in this study, although it is a fact that BC typically affects more women than 
men. The intervention is olaparib, in any dosage, either as a monotherapy or in combination with other 
therapies. The best trials will be phase 3 double blind randomised clinical trials, and have a placebo arm, or 
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comparator intervention(s). However given the infancy of the research into olaparib in BC patients, most studies 
will be phase 1 or 2, and some studies will be single arm.  Overall survival (OS) and longevity of progression 
free survival (PFS) are the ideal end points for patients.  However, RCTs measure how the intervention works, 
so the objective response rate (ORR) - complete response (CR), partial response (PR) or no response - will be 
the primary end point. Adverse events (AE) are also measured and discussed.  Analysis of the pharmacokinetic 
responses or any other focus are beyond the scope of this SR.    
Based on this PICO, the literature search question is ‘What is the Current Effectiveness of Olaparib for Patients 
with Breast Cancer and a BRCA Mutation?’ 
 
2.2 Search Strategy 
Figure 1 shows the methodical approach based on PRISMA guidelines for undertaking reviews using electronic 
databases to search the literature (supplemented by hand searching and cross referencing).  Literature search of 
databases was completedlast done in January 2018.  First there is an initial database search using key words - 
and identification of potentially relevant literature from all databases, as well as from grey literature.  After that, 
the literature is screened using the inclusion and exclusion criteria, followed by a decision about its quality, 
followed by a final decision to include that literature or not, with reasons why.   The resulting evidence should 
meet all the criteria to be included in the synthesis of the literature (21). 
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Figure1– PRISMA flow diagram (2009)  
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Initial searches on PRIMO were based on a predetermined series of keywords as follows:  Olaparib/Lynparza, 
Breast Cancer, and BRCA mutation (including all permutations). PRIMO database searches 179 databases 
including 43 databases under Nursing and Medicine – which include Core databases such as CINAHL, 
MEDLINE, Royal College of Nursing (RCN), Cochrane Library, Joanna Briggs Institute (JBI), CRD, 
Internurse, Embase, Google Scholar, PubMed. Searches of specialist databases (Cumulative Index to Nursing 
and Allied Health Literature (CINAHL), Cochrane library, Joanna Briggs Institute (JBI), National Health 
Service (NHS) website, and Clinical trials UK). Hand-searching and cross-referencing was also undertaken.  
The author contacted authors of several unpublished studies, as well as the UK’s leading expert on olaparib in 
BC patients with BRCAm (Professor James Tutt), and also the pharmaceutical company that manufactures 
olaparib to discuss trials they are involved in,  their transparency biomedical policy and ethical code of conduct. 
The date for inclusion of papers in this systematic review is begin at 2009, which is when Fong et al.’s (2009) 
key paper on maximum tolerated dose (MTD) of olaparib was published (22).  
After the literature search was undertaken, all preliminary scan or material to get a general sense of their 
contents and abstracts, next, iInclusion and Eexclusion Criteria were applied, these were: English language 
papers on BRCAm BC treated with olaparib, in scientific professional peer reviewed journals and conference 
proceedings, focussing on clinical effect were included.  Studies not focussed on breast cancer data, or BRCAm 
data, or PARPi other than olaparib were excluded.  Pre-clinical studies were not included.  Studies whose focus 
lies outside of clinical effectiveness were also not included.  
 
2.3 Quality Assessment and Eligibility for Inclusion   
Kmet et al. (23) was used for quality assessment, carried out independently by two independent assessors (the 
two authors) and the papers graded.  Kmet et al. (23) contains a 14-point checklist for assessing the quality of 
quantitative studies with scoring system for each category and whether the study meets that criteria or not (2 
points for yes, 1 point for partial, and 0 points for no) (23).   For this SR, the authors agreed a cut off score for 
inclusion as least 21 points out of a possible 28 points (75%).   All the studies eventually included in the review 
scored about 75%. 
2.4 Ethical issues 
As this is secondary research there is no need for ethical approval, however the primary research should all be 
approved by review boards and ethics committees for each trial centre.  
 
3. Results 
3.1 Meta-Analysis and Heterogeneity 
The quantitative synthesis of results obtained from different studies is termed meta-analysis (24).   Meta-
analysis can facilitate the synthesis of a large number of studies, and allow interpretation of studies with 
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different sizes and estimates.  As meta-analysis considers more than single study, there is less uncertainty and 
results can facilitate evidence based medicinedecision making in health care (17).  By collating information 
from different studies, meta-analysis can detect associations that a single study may not be able to provide.    
The aims of meta-analysis is to estimate an overall effect and whether the effect is similar or dissimilar.  If 
studies are relatively homogeneous they can be combined statistically and outcomes can be analysed and 
pooled.  Meta-analysis is usually presented as the extent to which a change based on an intervention was 
affected, and then presented in a forest plot (21).  Meta-analysis is a mathematical synthesis of the results of two 
or more primary studies that addressed a similar hypothesis (25).   
Deciding when a meta-analysis is appropriate can be difficult because there are several sources of heterogeneity 
to be considered.  If the designs, methods, quality, and results of the studies are deemed very heterogeneous, 
then statistically combining them can result in misleading conclusions. So a meta-analysis in this case would be 
inappropriate as it would be like attempting to ‘combineing apples and pears’ (17).  
It is important to consider the key clinical and methodological differences between the qualifying studies in 
order to assess their heterogeneity. Clinical differences include population - geography (UK, EU or global) and 
intervention (dosages) (17). Methodological differences would include study design (cohort, case study, 
experimental design), reported outcomes (end points such as ORR, OS, PFS), and timing of outcomes (17).   
As none of the studies in this SR address the same hypothesis in the same way, and have both clinical and 
methodological differences, a meta-analysis would not be appropriate, in which case, CRD (26) suggests that a 
narrative synthesis of studies, rather than statistically analysis, may be undertaken where studies are too 
heterogeneous (either clinically or methodologically) to combine.  This approach clarified the similarities and 
differences among studies that appear to address the same or similar research questions (26).  
Figure 2 details the results of the search strategy in a PRISMA diagram and shows that 1157 records were found 
on PRIMO and ordered by relevance. The top 100 records were screened.  Ninety studies were rejected and ten 
full texts were retrieved and read. Three records were rejected.  All articles passed the quality assessment for 
inclusion.  Seven studies met and passed all the criteria for inclusion in quantitative synthesis.  All seven met the 
minimum Kmet threshold score of 75%.   
Figure 2: PRISMA diagram completed 
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PRIMO  (1157 records ordered by relevance) 
CINAHL plus (23 duplicates)   Cochrane Library (2 duplicate) 
Royal College of Nursing    CRD 
PUBMED                               NHS evidence (23 duplicates) 
Medline      JBI     
Embase                                                 Hand search (1 – LEE 2014)   
Grey (0)     TOTAL N= 1158   
                 Total N = 1158  
First 100 articles (ordered 
by relevance) abstracts 
read.    
N = 100               
 10 articles - Full text 
retrieved  
                N=10  
Grey literature =  0 
Confirmation from AZ all 
trials were included 
    (N=0) 
 Exclusions 
Other PARPi used  
No BRCAm data 
Studies not examining 
Breast Cancer 
Studies not focussed on 
clinical effectiveness 
Articles excluded after quality 
assessment   = 0 
                      (N=0) 
 Records excluded = 
90 (not examining 
Olaparib, or Breast 
Cancer or BRCA 
mutations)  
 
(N=90)  
 Full text 
articles 
excluded  
Dent 2013 
Lee 2014 
Lee 2017 
(N= 3)  
Dent study was 
ovarian cancer,    
and Lee (2014) 
focus was 
biomarker 
analysis and Lee 
(2017) was 
TNBC (no 
BRCAm) 
Studies Included in the narrative synthesis = 7 
                                        N= 7 
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Author Study design 
Methods of 
data 
collection 
and 
analysis 
Objective 
Response 
Results in 
BRCAm cohorts 
Olaparib dose 
No. of 
Patients  
(No. with 
BRCAm 
BC)  
 Comments 
Fong 2009 
Phase 1 non 
randomised 
open label dose 
finding trial 
using 3+3 
design. 
Single arm 
monotherapy 
ORR, CR, 
PR 
measured 
using 
RECIST 
and CT or 
MRI scan. 
AEs 
measured 
using 
CTCAE 
33% at 400mg BiD 10‐600 BID 60 (3)  
Very small cohort.  No 
written consent found.  
First in human trial.   
MTD found at 400 BiD 
Tutt 2010 
Phase 2 non 
randomised 
proof of 
concept open 
label  
monotherapy 
ORR,CR, 
PR 
measured 
using 
RECIST 
and  CT  or 
MRI scan, 
AEs 
measured 
using 
CTCAE 
41% at 400mg  
BiD 
22% at 100 BiD 
400 or 100 BID 54 (54)  
Comparator arm on 
lower dose (100mg) = 
MTD is most effective. 
Gelmon 
2011 
Phase 2 non 
randomised 
Open label 
Four cancers 
studied. 
monotherapy 
ORR,CR, 
PR 
measured 
using 
RECIST 
and  CT  or 
MRI scan, 
AEs 
measured 
using 
CTCAE 
0% 400 BID 90 (10)  
 Compares results 
between BRCAm or 
BRCAwt.  Very small 
cohort.   Heavily treated 
- 70% > 3 prior 
chemotherapy,  
 TNBC = large 
heterogeneity among 
patients.  
3 patients data not 
confirmed.  
Balmana 
2014 
Phase 1 non 
randomised 
dose finding 
trial, 3+ 3 
design. 
Open label 
Combination 
therapy (with 
cisplatin) 
ORR,CR, 
PR 
measured 
using 
RECIST 
and  CT  or 
MRI scan, 
AEs 
measured 
using 
CTCAE 
71% 
SD (>1 year) 
occurred in 5 breast 
cancer patients 
50‐200 BID 
(continuous and 
intermittent dosing 
schedules) 
53 (17)  
 Patients BRCA status 
not centrally validated 
Small cohort. cisplatin 
60 mg/m
2
 with 
intermittent olaparib 50 
mg BID deemed 
tolerable but MTD not 
reached 
Van der 
Noll 2015 
Open label 
Monotherapy 
long term 
safety study 
following a 
Phase 1 single 
arm 
combination 
study (olaparib 
with 
AEs 
measured 
using 
CTCAE 
N/A 400BiD 21 (5)  
No written consent 
found.  AEs reduced 
over time suggesting 
carry over from prior 
chemotherapy study. 
Mistake found in results 
text.  Patients on 
therapy for up to 3.5 
years. 
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carboplatin 
and/or 
paclitaxel). 
Kaufman 
2015 
Phase 2 non 
randomised 
Open label 
single arm 
monotherapy 
ORR,CR, 
PR 
measured 
using 
RECIST 
and  CT  or 
MRI scan, 
AEs 
measured 
using 
CTCAE 
12.9% 400 BID 317 (62)  
Very heavily pre-
treated (average 4.6 
prior therapies). No 
written consent found. 
47% SD is a very good 
response rate given the 
heavy pre-treatment of 
these patients.  
 
Robson 
2017 
Phase 3 
randomised 
Open label  
monotherapy 
ORR,CR, 
PR 
measured 
using 
RECIST 
and  CT  or 
MRI scan, 
AEs 
measured 
using 
CTCAE 
59.9% 300 BID (tablet form) 302 (302)  
Not truly randomised as 
physicians choice was 
limited - and no placebo 
arm.  Least pre-treated 
cohort with some 
patients only one prior 
treatment.  Also 
measured QoL and 
PFS2.  End point PFS 
was reached.   
 
 
Table 1: papers included in the review.   
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Table 1 shows the papers that were included in the review. 
 
In addition to searching on PRIMO, separate searches were conducted on Cumulative Index to Nursing and 
Allied Health Literature (CINAHL) (23 records found but none additional), and Cochrane Library (2 records 
found (not additional) plus several abstracts), Centre for Reviews and Dissemination (CRD) (no records found) 
and Joanna Briggs Institute (JBI) (no records found), National Health Service (NHS) Evidence (23 records 
found but non additional), and National Institute for Health and Care Excellence (NICE) (2 records found, but 
none additional).  
Hand sSearching and cross referencing found no additional studies, while grey literature search found no 
studies, but it did provide some current information from Professor James Tutt, one of the leading researchers in 
this field.  
To elaborate on grey literature: , an hour long conversation was held with the Medical Officer at AZ (who 
manufacture olaparib), who confirmed that, in his opinion, that all the existing studies he is aware of are 
included in this SR.  He also confirmed that in OlympiA (NCT02032823), which is  - an ongoing phase 3 RCT 
sponsored by AZ, ) results were not available yet (originally due out in summer 2018 and now not expected 
until summer 2020) due to patient survival.   The end point was a set number of AEs, which has not been 
reached at this time of writing.  Neo - Olympia is another phase three 3 trial looking at olaparib monotherapy in 
patients pre-ior and post-surgery, but the trial is ongoing and there are no results available yet.   OlympiA, neo-
Olympia and OlympiAD are the only phase 3 trials to date looking at effectiveness of olaparib in BC patients 
with BRCAm. 
Professor Balmana was also contacted to ask about her recent research ‘Phase I, Open-Label, 2 Part Multicentre 
Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With 
Advanced HER-2 Negative Breast Cancer’ (NCT02561832) and she replied to say that the trial stopped 
recruitment early and there is no efficacy data. .  The authors did not receive a reply about   Aanother ongoing 
trial by Abraham et al. did not reply, although it is appears likely that this study  tois  only just be starting.   This 
is a randomised phase 2/3 trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based 
neoadjuvant chemotherapy in triple negative and/or germline BRCAm breast cancer patients (27). 
3.1 Detailed Narrative Review and Critical Appraisal   
Six of the trials in this review are experimental, while one (28) is a long term case study.  All seven clinical 
trials in this SR vary in methods used.  As shown in table 1, all but Tutt et al. (29) and Robson et al. (30) are 
single arm studies.  The interventions are different – Fong et al. (22) and Balmana et al. (31) are dose- finding 
trials with increasing doses of olaparib.  Fong et al. (22), Tutt et al. (29), Gelmon et al. (32), Kaufmann et al. 
(33), Van der Noll et al. (28)  and Robson et al. (30) study olaparib monotherapy at MTD while Balmana et al. 
(31) investigate a combination therapy of olaparib with platinum treatment.  None of the trials are randomised 
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except Robson et al. (30) where patients were randomised to olaparib therapy or one of three therapies of 
physician’s choice. Table 3 shows the methodologies of the included studies. 
Table 2. Methodologies of included studies 
Study 
reference 
Study 
design 
Single arm 
or 
comparator 
Combinatio
n or mon 
therapy? 
Country or 
internationa
l 
Clinical trial 
number 
Ethical 
approval 
Fong 
2009 
Phase 1  
non-
randomised  
dose finding 
trial 
Single arm monotherapy UK (Royal 
Marsden) 
and 
Netherlands 
(Cancer 
Institute) 
NCT0051637
3 
Non 
mentioned 
Tutt 
2010 
Phase 2 
Non-
randomised 
Proof of 
concept 
Sequential 
cohort 
Comparator 
arm on lower 
dose (100mg) 
Monotherapy Multinational 
– 26 centres 
across 
Australia, 
Germany, 
Spain, 
Sweden, UK 
and USA. 
NCT0049423
4 
Written 
informed 
consent 
Study 
approved by 
independent 
ethics 
committee for 
each trial 
centres, done 
in accordance 
with good 
clinical 
practice 
guidelines 
and 
Declaration 
of Helsinki 
Gelmon 
2011 
Phase 2 
Non-
randomised 
Open-label 
Single arm 
but can 
compares 
results 
between 
BRCAm or 
BRCAwt 
monotherapy 6 centres 
across 
Canada.  
NCT0067978
3 
Written 
informed 
consent.  
Study 
protocol 
approved by 
health 
Canada and 
institutional 
review boards 
and the six 
particiapating 
sites.  
Balmana 
2014 
Phase 1` 
Non-
randomised 
Dose finding 
trial 
Single arm Combination 
therapy 
(olaparib 
with 
cisplatin) 
Multi centre 
– country not 
stated but 
Balmana 
works out of 
University 
Hospital in 
Barcelona. 
NCT0078257
4 
Study carried 
out in 
accordance 
with 
declaration of 
Helsinki, 
good clinical 
practice and 
AZ policy on 
bioethics. 
Kaufma
n 2015 
Phase 2 
Non-
randomised 
 
Single arm 
but can 
compare 
different 
monotherapy Multinational 
– 13 centres 
across Israel, 
Australia, 
NCT0107866
2 
Written 
informed 
consent. 
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cancer types 
(ovarian, 
breast, 
pancreas, 
prostate and 
other) 
Germany, 
Spain, 
Sweden and 
USA 
Study carried 
out in 
accordance 
with 
international 
conference on 
harmonisatio
n good 
clinical 
practice 
guidelines 
and 
declaration of 
Helsinki and 
approved by 
independent 
ethics 
committee or 
institutional 
review board 
at every trial 
centre.  
Van der 
Noll 
2015 
Long term 
monotherap
y safety 
study,  
following a 
phase 1 
combination 
study  
Single arm 
but can 
compare 
different 
cancer types 
(breast, 
ovarian and 
fallopian 
tube). 
Monotherapy 
long term 
safety study 
following a 
Phase 1 
combination 
study 
(olaparib 
with 
carboplatin 
and/or 
paclitaxel).  
Netherlands 
Cancer 
Institute 
n/a No mention 
of ethical 
approval  
Robson 
2017 
Phase 3  
Randomised 
Open-label 
Comparator 
arm was 
standard 
single 
chemotherap
y  of 
physicians 
choice 
(capecitabine, 
eribulin, or 
vinorelbine) 
monotherapy International 
– multi 
centres 
across 19 
countries 
(Bulgaria, 
China, Czech 
Republic, 
France, 
Hungary, 
Italy, Japan, 
Korea, 
Mexico, 
Peru, Poland, 
Romania, 
Russia, 
Spain, 
Switzerland, 
Taiwan, 
Turkey, UK 
and USA..  
NCT0200062
2 
Protocol 
approved by 
ethics written 
informed 
consent.  
review 
committees at 
participating 
institutions  
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The Consolidated Standards of Reporting Trials (CONSORT) is a checklist and flow diagram that was 
developed to improve the transparency and quality of reporting of RCTs, and to improve reliability and validity 
of trial findings (19).  All trials in this SR were found to abide by the CONSORT checklist (34).   However, 
none of the trials (except Robson et al. (30)) in this SR used randomisation or blinding so those sections of the 
CONSORT checklist and diagram were not reported (except Robson et al. (30)).   The CONSORT 2010 
Statement, and website (www.consort-statement.org) also helps authors to critically appraise and interpret 
RCTs, and extract information for SRs, and the CONSORT checklist 2010 was used for this purpose  
RCTs or true experiments are the most robust design for testing cause and effect relationships (e.g., whether a 
treatment or intervention affects outcomes) (35). A RCT is an experiment with a random allocation of 
participants between experimental and control groups. The outcomes of the groups can then be compared (36). 
For a RCT to be a true experiment, the following features apply: comparison and placebo arms, sampling and 
demographic equality at baseline, sample size estimation and power calculation, blinding and randomisation, 
drop-out rates and patient loss, publication bias and ethics and consent (21).  How these features appear in the 
studies within this SR is discussed below. RCTs in this SR were also examined for variation in study end points 
and data collection and analysis methods in order to collect all the evidence (37).   
3.1.1 Comparison and placebo arms  
Comparator arms are important in order to be sure that the effects noted are due to the actions of the 
intervention, and not due to anything else (17, 38).  Variables are manipulated and outcomes assessed between 
the experimental and control groups, so bias and other confounders can be controlled, and factored out, and 
external influences removed,   - so that researchers can be sure effects noted are due to actions of the 
intervention and nothing else (17).    However only Robson et al. (30) study had true comparator arms with 
patients taking different interventions (although Van der Noll et al. (28) and Kaufman et al. (33) could compare 
results between different cancers, while Tutt et al. (29) could compare different dosages and Gelmon et al. (32) 
could compare BRCAm with BRCAwt results.   
For trials like the ones in this SR that are not placebo-controlled, there is no comparator so results may be 
misleading or biased, especially when it comes to reporting efficacy of treatments (39). Placebo arms are 
required to test a hypothesis, but being as there were no placebo arms in any RCTs, this reduces the external 
validity of results of all the studies and is a serious limitation to this SR.   Additional weaknesses to Robson et 
al.’s (30) trial are highlighted by a lack of a platinum-based chemotherapy comparator arm, which seems strange 
given the evidence of platinum sensitivity correlating to olaparib sensitivity noted in previous studies (3,4,5).  
RCTs with comparator arms and large sample sizes provide the most reliable evidence regarding the efficacy of 
healthcare interventions (36), however this is not the case with the seven studies considered as part of this SR. 
 
3.1.2 Sampling and demographic equality of groups at baseline.   
It is not possible to include all potentially eligible subjects of a population so samples are taken and these should 
be random (21).  Data from randomly selected samples are generalisable to the target population and sometimes 
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beyond (to similar populations and settings) (17). However sampling for the trials within this SR has been 
dictated by a specific characteristic in a population (BC with BRCAm), so sample sizes are often small, not 
randomly selected and results are relevant only for this subset of patients.  Sacket et al. (40) reminds us however 
that evidence based medicine is not restricted to randomised RCTs and that to find out about a specific therapy 
for a specific group of patients, then we need studies using those patients who harbour the relevant disorder (in 
this case BC with BRCAm). So selection bias in these RCTs is not a factor, as selection bias only occurs when 
the participants are not a true representative sample of the target population about whom the conclusions will be 
drawn (41).  
Baseline demographic characteristics of patients were all similar in these studies, and are balanced between the 
treatment groups (age, gender, nationality, geography) (17).  Baseline information is most efficiently presented 
in a table (39) which was the case in all studies in this SR.  All studies measured the same patient baseline 
characteristics (sex, age, tumour type and size, Eastern Cooperative Oncology Group (ECOG) performance 
status, and number of prior treatments) thus ensuring patient characteristics were as similar as they could be at 
baseline.   
All trials assessed patients over 18 years of age with overall average of 44 years.  The vast majority of patients 
were female although gender was not an inclusion/exclusion criteria in any study.   Fong et al. (22), Tutt et al. 
(29), Kaufmann et al. (33) and Robson et al. (30) studies are multi-national while Balmana et al. (31) and 
Gelmon et al. (32) are multi-centre studies so patients were assessed from all over the world (EU, Australia, 
Israel, Canada and USA).  It is beyond the scope of this review to assess the benefits or downfalls of a multi-
centre or multi-national collaboration on clinical trials, but there is the question of confounding factors such as 
differences in equipment, methods, and personal opinions of different researchers between such diverse 
locations, compared to a study conducted in one central laboratory.  However, multi-centre studies are 
considered excellent sources of evidence for evaluating healthcare interventions (17, 42).   
 
3.1.3 Sample size  
Large scale, multi-site RCTs are often required to establish superiority of one treatment over another (17). 
However, very few of the trials in this SR had large sample sizes, which is understandable because the condition 
under investigation (BC patients with BRCAm) is not usual to the general population (38).   All studies except 
Tutt et al. (29), Kaufman et al. (33) and Robson et al. (30) have a very small sample size of patients (3-17 
individuals), leading to the potential that some results from small cohorts could always be due to chance. Fong 
et al. (2009) had only nine BC patients (15%) and of those, only three had BRCAm, so these are very small 
numbers indeed. Small sample sizes is a potential  limitation of the papers included in to this SR because large 
samples are necessary to detect small differences in effect size (39).   
Future large scale trials are required to provide more externally valid reliable results, because trials with 
inadequate samples sizes (like most in this SR) are associated with bias, as having too few patients runs the risk 
of missing statistically significant findings (21) due to type II errors..    
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3.1.4 Blinding and Randomisation  
 
Being aware of which interventions the control and experimental groups are receiving may introduce bias on the 
part of the subjects and researchers (17). Blinding the groups of individuals (participants, researchers, or data 
collectors) who can introduce bias into a trial is crucial for successful randomisation (39).   
 
Robson et al.’s (30) OlympiAD trial is the first and only trial in this SR to be randomised.   However, this trial 
was also open-label (unblinded) which may influence participant’s compliance with the intervention, or risk 
participants dropping out of the trial. Participants may respond differently if they know which treatment group 
they are assigned to (e.g. by responding more positively when know they are receiving the new treatment) (17). 
 
Unfortunately, all studies in this SR are open label, so participants could introduce biases as above, and 
researchers may also introduce different biases.   Moher et al. (39) suggest that unblinded researchers may 
assess subjective outcomes differently. Unblinded data analysts might introduce prejudice through biased 
selection of positive results, or by making decisions to remove patients with unfavourable results from the 
analyses.  Random assignment is the preferred method to assign interventions to trial participants, and when 
properly implemented, it eliminates bias in the assignment of treatments (39). Without randomisation, treatment 
comparisons and results can be biased, even subconsciously (17). This lack of randomisation and blinding in the 
all the trials in this SR imposes a limitation of this SR because randomisation is such as this is a crucial 
component of high quality RCTs (39).   
 
 
3.1.5 Dropout Rate and Patient Losses 
If patients do not complete the study then data is lost and outcomes not fully assessed (21).  This may be 
because of AEs, voluntary withdrawal, secondary disease or death.   The rate of Rretention of patients  rate is 
very important in any study. If a large percentage of participants withdraw from the study, or choose to drop out 
for any reason, the results are likely to be different than if all of the participants had remained oin the study, 
since patients with specific characteristics may be more likely to drop out or be forced to discontinue (35).   
‘Intention to treat’ analysis was used in all studies in their SR, which means patients were analysed in the group 
to which they were originally assigned.   
It is not uncommon for participants not to complete a study—they may drop out for their own reasons or be 
withdrawn from active treatment due to adverse effects (related to the treatment or otherwise) —and therefore 
their outcomes are not assessed at the end of a trial (39).  Despite reporting of several patients dropping out in 
the trials in this SR, all patients were accounted for, and their results were included in the analysis if they had 
had at least one dose of olaparib, given that ORR had to be confirmed at a second assessment four weeks later.    
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3.1.6 Publication Bias  
Every researcher has an ethical obligation to publish complete and accurate research results of all trials with 
human participants (43, 44). However, for many reasons, not all research results are published in an accurate 
way, and in some cases they are not released at all (45).  Publication bias may occur after manuscripts are 
submitted to a journal, as well as before.  Publication bias like this creates a false impression on the reliability of 
these clinical trials, and also affects the clinical conclusions about the best treatments, which is an issue for 
evidence based practice (45). 
A clear finding from this SR, based on the results of all in all but one study (22) (as this study was published 
prior to AZ acquisition of the company that made olaparib) of these trials is the risk of publication bias.  Risk of 
Ppublication bias risk is particularly highlighted in Robson et al.’s (30) trial, as .  Tthe 2.8 months PFS benefit in 
Robson et al’s (30) trial was measured by blinded independent central review.  However, it is interesting to note 
that when the same data was assessed by the investigator, the PFS benefit of olaparib was 4 months (7.8 months 
PFS in olaparib versus 3.8 in standard).    The authors say their 4 months is similar to the blinded central review 
result of 2.8 months, but there is a 1.2 month gap which is certainly significant when the independent review 
result was only initially 2.8 months to start with.    Another misleading statement by Robson et al (30) is that the 
risk of disease progression or death was 42% lower – however the results show patients have not actually lived 
for longer when taking olaparib versus TPC so this suggests there may be some bias reporting.     
Almost all of the research into olaparib is funded by one pharmaceutical company (AZ), or undertaken in 
collaboration with them, or assistance given with writing up (31,32,33), so there is a need to assess the level of 
bias in the reporting and publishing of these trials.    In all of the trials in this SR, AZ was the major sponsor 
with researchers and authors having connections to AZ, or will benefit in other ways if olaparib proves to be a 
success.  In Robson et al.’s (30), AZ was responsible for overseeing the collection, analysis, and interpretation 
of the data.  The manuscript was written with medical-writing support funded by AZ, with critical review and 
input from authors (30).    Although in no way seeking to question the integrity of AZ as a company, or of any 
of its employees or researchers, it may not be helpful in establishing the clinical efficacy of olaparib for one 
company to so completely dominate the research agenda. It is difficult to see how this may be ameliorated, 
however, given the huge expense involved in the development of new medicines. Recent developments in 
clinical trials registration and in publishing, including transparent reporting of potential conflicts of interest, are 
welcome in this regard. 
 
3.1.7 Ethics and Consent  
Beauchamp & Childress (46) suggest that there are fundamental ethical principles that all researchers should 
abide by including: autonomy, beneficence, non- malevolence (do no harm), and informed consent, as well as 
the right for participants to refuse to participate or change their mind without prejudice, the right to revoke their 
permission to use their data, and even how their data is anonymised and accessed (17).   The World Health 
Organisation (WHO) advise that authors of SRs of primary research identify how these principles were put into 
practice in order to protect the participants (47).   However of the seven trials of this SR, major ethical 
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weaknesses were found in three.  There is no patient consent mentioned in three studies (22, 28, 33). Informed 
consent by study participants is normally required in all intervention studies (39), and without full 
documentation of ethical considerations, concerns are raised because without proof participants understood the 
nature and stage of the disease being studied, the study may include persons vulnerable to harm from the study 
intervention, and this raise issues as to whether these studies satisfy WHO as above, as well as other legal and 
ethical norms (39).   
 
3.2 Methods of Data Collection and Analysis 
Critical appraisal of the quality of RCTs is possible only if the design and methods of data collection and 
analysis are thoroughly and accurately described in the published literature (39) 
Despite the heterogeneity of the studies in this review, all methods used in all trials were described thoroughly.  
Recognised standard methods of data collection and analysis were used, and in many cases the same methods 
were used in other trials, enabling valid and reliable comparisons to be drawn between the studies where it was 
possible (17).   
Both dose finding trials (22, 31) used a standard 3+3 dose-finding method – this means treating at least three3 
assessable patients per dose for one cycle, with a doubling of the dose in the absence of AE of grade 2 (22) at 
that dosage - or grade 3 (31). Each cohort was expanded to six6 or more when olaparib dose was increased or if 
one dose-limiting toxicity (DLT) was observed at a given dose.  A dose was considered the MTD if two2 
manifestations of DLT were observed at that dose during first treatment cycle.  A drug related AE of grade 3 or 
4 occurring in the first cycle was considered a DLT.   
Another finding of these studies was that they all measured objective response rates (ORR) (CR or PR) using 
the recognised Response Evaluation Criteria in Solid Tumours (RECIST) (49), and all studies assessed 
radiological response by means of computed tomography (CT) or magnetic resonance imaging (MRI) – which 
were carried out at least 28 days initially (22, 28, 29, 33).  An additional strength of Robson et al. (30) was that 
the authors also assessed overall survival (OS) although this was not the primary end point (PFS was primary 
end point), and assessed the time to second progression event or death after first progression event.   
In every study, the analyses of measurable response was done for all patients who had had at least one dose of 
olaparib. Importantly for precision of results, all trials ensured 95% confidence intervals (CASP and CONSORT 
(34)), which were measured using the recognised Wilson score method as recommended by Newcombe and 
Altman (50).   Confidence intervals (CIs) are the best indicators of the precision e nature (or not) of the result 
values (35), as . For example, a 95% CI is a range of values within which the reader can be 95% confident the 
true value lies for the studywhole population. (i.e. the population the study patients were selected from). 
The olaparib dose used in Robson et al.’s (30) study is different from the FDA-approved 400-mg twice- daily 
dose in capsule formulation used in all the previous trials in this review.   Tablets give a higher exposure while 
the adverse effects are not expected to be different (30), however how much difference the dosage and delivery 
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method of olaparib makes is outside the scope of this review but is something that should be determined by 
future investigations and analysis.    
Where BRCAm analysis was done, the validated and approved external central reference laboratory Myriad 
Genetic Laboratories carried out the analysis (this is the laboratory that was granted the sole rights to perform 
these tests since 2014).   A weakness of Balmana et al.’s (2014) trial is that they did not originally test for 
BRCAm.  However due to a protocol amendment, BRCAm status was collected for patients who had previously 
been tested for gBRCAm – but as these patients BRCAm status is not centrally validated by Myriad Genetic 
Laboratories results must be treated with some caution.  The same caution applies to Kaufman et a.l.’s (33) 
results as patients’ BRCA status was not centrally validated. 
Data was collected and analysed wholly or in part by a third party in some of the trials (22, 29, 33) which leads 
to reduction of potential bias in these studies.  In others however, data collection and analysis was done by AZ 
themselves, with interpretation by the authors in collaboration with the sponsor. Gelmon et al. (32) admitted that 
there was no independent review of responses done in her trial, but where statistical analyses was done (29, 31) 
a recognised system using SAS software (version 8 or 9) was used.   
PFS (assessed by RESIST) plots were created using the recognised Kaplan Meier method,  - and Robson et al 
(30) also used Kaplan Meier method to generate time to event curves.   
Additional validity and reliability for adverse events (AE) data was provided by an independent data monitoring 
committee who reviewed Tutt et al.’s (29) safety data, but this was not something mentioned for AE in any other 
trial.  However, all AEs in all trials were graded according to the standard and recognised Common 
Terminology Criteria for Adverse Events (CTCAE, 51).   
Overall, the approved methods used for data collection and analyses in these studies abide by the CONSORT 
checklist, with results for all analyses performed, including subgroup analyses (39). 
  
3.3 Study End Points     
In oncology trials, an increase in overall survival (OS) is the most convincing measure of drug efficacy and 
patient benefit (52).  Measuring OS requires extended follow‐up with large numbers of participants, so OS 
results may be confounded by the use of rescue therapies during this time. To address this limitation, recent 
studies have introduced a range of intermediate endpoints such as progression‐free survival (PFS) and time to 
progressive disease (PD).  Researchers in the RCTs in this SR subcategorise ORR in terms of complete response 
(CR), partial response (PR) or stable disease (SD) (52). 
Overall survival (OS) is the gold standard for oncology trials, followed by PFS and then ORR (39).  However, 
all studies in this SR assess PFS as primary end point rather than OS.  PFS seems acceptable when survival is 
good as it takes a long time to get the OS data, but for patients with BRCAm BC who have already progressed 
on two or more previous lines of therapy (which all these patients in these trials have), then the OS is short.    It 
would have been far more reliable and more valid to have been able to assess the OS of BRCAm patients taking 
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olaparib for BC.      Although Robson et al. (3) did assess OS in their study, the primary end point was PFS so 
despite the OlympiAD trial having met its primary endpoint, without the full data on OS the true clinical 
effectiveness of olaparib cannot be certain.   
One weakness of RCTs is that they tell us nothing on their own about the patient’s experience (21). There are 
also concerns regarding whether olaparib improves meaningful outcomes for these patients other than clinical 
effectiveness, such as appropriateness and feasibility (42).  Evidence based medicine requires any external 
evidence to be integrated with an individual patient’s clinical state and personal preferences (40) which was not 
the case for the trials in this SR (except 30, where Quality of Life was included as a secondary study end point)..   
Therefore, future trials should go on for longer and include OS results, which would mean data for assessing 
effectiveness of olaparib is more reliable and free of bias.  However, as explained by AZ’s medical officer, trials 
could go on for a very long time, e.g. OlympiA.   Given the apparent benefit of olaparib for these patients, it 
could be argued that it is better to have more results sooner, rather than wait for confirmed OS data which may 
take years, i.e. questions about some therapies cannot wait for large scale, long term trials to be conducted (40). 
 
3.4 Overall Synthesis 
The major limitation of the studies included in this SR is their lack of randomisation in the studies to date and 
lack of proper control/placebo arms.  Even in Robson et al.’s (30) randomised phase 3 trial which did have 
comparator arms, neither the patients nor the researchers were blinded.  Another major limitation of this SR is 
the small number of trials to date,  – and within those trials, the small sample sizes who fit the criteria of having 
BC and BRCAm – - there are cohorts of 17 or less in over half of the trials (22, 28, 31, 32).  
Despite patient demographics being consistent, and methods of data collection and analysis recognised, 
producing valid ORRs, the number of studies, the small sample sizes and heterogeneous nature of the trials in 
this SR prevented a statistical meta-analysis being undertaken. 
AZ did confirm that all studies they are aware of have been sourced for this SR,  – and despite a limited there 
not being a lot of number of studies evidence to date, it is clear from the studies included here that so far the 
evidence contains similar themes and overall there is a benefit of olaparib therapy (monotherapy or combination 
therapy) over standard therapy. , so lLarger, longer term trials with more comparator arms should be undertaken 
if this to prove this hypothesis is to be substantiated. 
The main ORRs are shown for comparison in the table 3 below.  
 
 
Table 3 - Objective Response Results for all Trials in this Systematic Review.   
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Author Therapy Phase 
 Type of 
cancer 
Olaparib dose 
No. of 
Patients  
(No. with 
BRCAm 
BC)  
MTD (dose 
finding trails 
only) 
Objective Response 
Results in BRCAm 
cohorts 
Fong 
2009 
Olaparib 1 
Solid 
tumours 
10‐600 BID 60 (3) 400 mg BID  33%   
Tutt 2010 Olaparib 2 
BRCAm 
breast cancer  
400 or 100 
BID 
54 (54) — 
41% at 400 mg BID, 
22% at 100 mg BID 
Gelmon 
2011 
Olaparib 2 
BRCAm 
breast cancer 
and ovarian 
cancer  
400 BID 90 (10) —  0%  
Balmana 
2014 
Olaparib 
plus 
Cisplatin 
1 
Breast, 
ovarian, 
pancreatic, 
peritoneal 
cancers 
50‐200 BID 
(continuous 
and 
intermittent 
dosing 
schedules) 
53 (17) 
cisplatin 60 mg/m
2
 
with intermittent 
olaparib 50 mg 
BID deemed 
tolerable but MTD 
not reached  
 71%   
Lee 2014 
Olaparib 
plus 
Carboplatin 
1/1b 
BRCAm 
breast cancer 
and ovarian 
cancer  
100‐400 BID 
(continuous 
and 
intermittent 
dosing 
schedules) 
45 (8) 
carboplatin AUC 5 
with intermittent 
olaparib 400 mg 
BID  was highest 
tested dose but 
MTD not reached  
87.5%  
Kaufman 
2015 
Olaparib 2 
Various 
BRCAm 
cancers  
400 BID 317 (62) — 12.9%   
Robson 
2017 
Olaparib 3 
BRCAm 
breast cancer  
300 BID 302 (302) — 
59.9%  
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The ORR was not measured in Van der Noll et al.’s (28) long term safety study, so no results are shown, 
however, results of Lee et al.’s (6) combination study (did not meet all inclusion criteria for SR) are included for 
interest and comparison with Balmana et al.’s (31) combination trial.  
Clinical effectiveness has been measured in all the trials in this review as the Objective Response Rate (ORR).   
Despite ORRs varying wildly from zero response (32), to 71% (31), the overall clinical benefit of olaparib 
appears to be greater and longer lived in BRCAm carriers compared to BRCAwt, and also when compared to 
standard chemotherapy treatments.       
Tutt et al. (29) reported 400mg BiD shows a near doubling of ORR when compared to patients on lower 100mg 
BiD  (41% versus 22%), and median reduction in tumour size was of -30% compared to only -7% for the 100mg 
cohort suggesting the MTD is the most clinically effective.    The presence of a dose-response result is 
recognised as an important criteria for believing there to be a reputed cause and effect relationship.  
Long term monotherapy also reported good results, with Van der Noll et al. (28) reporting 43% of all patients 
still on the study at the time of data cut off, including four patients who had been on the study for over 2 years - 
43% with CR, 22% PR, and 29% SD.  Only 5% of patients showed PD.  
When compared to standard chemotherapy, olaparib showed improved clinical effectiveness.  In Robson et al.’s 
(30) trial comparing olaparib with standard chemotherapies, ORR in the olaparib cohort doubled (59·9% 
compared with 28·8%), and CR was seen in 9% of olaparib group versus just 1.5% in TPC group.  Further 
encouraging results show that the tumour reduction of -45.1% for olaparib arm compared to 14.8% for TPC 
arm.      
The studies that reported zero or low ORR are important to consider.  Gelmon et al. (32) saw no ORR in BC 
cohorts at all, while Kaufman et al. (32) saw ORR of only 12.9%.  Despite no ORR to olaparib monotherapy for 
any of the BC patients, it is important to note that there was clinical benefit.  SD was seen in 63% in BRCAm 
cohort compared to 13% in the BRCAwt cohort.   PD in BRCAm cohort was less than half that seen in the 
BRCAwt cohort (38% versus 80%), and despite not being included in the final confirmed results, 50% of 
BRCAm patients saw tumours reduce in size by more than 30%, which definitely warrants further exploration.    
Clinical benefit was also derived in one trail (33) as 47% of the BRCAm BC cohort maintained SD which was 
higher than any other cancer type in this trial. 
Overall, whilst the number of trials to date is small, and the patient cohort size within those trials is often even 
smaller, the overall results suggest that olaparib does show clinical effectiveness for BC patients with BRCAm.    
In Fong et al.’s (22) study, the  clinical benefit rates for patients with BC and BRCAm were 69% in platinum  
sensitive patients, 45% in platinum resistant patients,  and 23% in platinum refractory patients, suggesting a link 
between platinum resistance and olaparib response; that.  I.e. – platinum sensitive patients will benefit the most 
from olaparib therapy.  In Gelmon et al.’s (32) trial - responses were also consistent with prior platinum 
sensitivity as post hoc analysis showed activity mostly in patients with platinum sensitive disease.    
This hypothesis gains strength as the studies continue with 62 platinum resistant BC patients (33) with at least 
three  3 lines of prior therapies (median of 4.6) resulting in ORR of 12.9%, compared to minimum of 1 
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treatment and median of three3 treatments in  another (29),  which resulted in ORR of 41%.  In addition, 
although the ECOG status was the same in both trials (ECOG range 0-2), Kaufman et al. (33)) had more patients 
with ECOG of 2 (which means they have longer cancer history which tallies with the higher pre-treatments) 
than Tutt et al. (29).  Gelmon et al. (32) results showed zero response to olaparib but 70% of the BRCAm BC 
patients had had at least 3 prior lines of chemotherapy, so were also heavily pre-treated, while in Robson et al’s 
(30) trial, the superiority of olaparib was even more pronounced in patients without prior platinum exposure.    
Of particular note in Kaufman et al.’s (33) trial, there was a doubling of response in BC patients (20% versus 
9.5%) who had not had prior platinum treatment.   
Consistent across all the trials in this review, the clinical benefit rates seem to correlate to platinum sensitivity, 
suggesting that platinum sensitivity may be a surrogate marker for sensitivity to olaparib treatment.   Indeed 
looking at the results of all studies it appears that platinum sensitivity may be enough to predict a response to 
olaparib.    For all the trials that measured it, there was also consistent association between clinical benefit and 
platinum free interval (the period between last platinum therapy, and disease progression) which should be 
explored in longer term studies in the future.    
Mechanisms of resistance are not measured in any of the trials and is outside of the scope of this SR,  - but it is 
certainly something for future investigation in order to understand the relationship between prior platinum 
exposure and response to olaparib.   Unfortunately, in Robinson’s et al.’s (30) trial, there was no platinum based 
chemotherapy to compare with olaparib.   It is encouraging that efficacy was seen in patients with prior platinum 
exposure, however it was outside the scope of the trial so assess effectiveness of olaparib in patients with 
platinum resistant disease.   Considering the high success rate seen by Lee et al. (2014) (6), carboplatin as a 
control arm in Robson et al.’s (30) trial would have been the ideal control to test the efficacy of olaparib 
compared to carboplatin.    Although previous treatment with carboplatin was allowed in Robson et al.’s (30) 
trial, only 14% of patients had received platinum previously and subgroup analysis shows that the superiority of 
olaparib was even more pronounced in patients without prior platinum exposure.  Further research into the link 
between platinum sensitivity and response to olaparib is warranted.  
A consistent theme throughout all the trials in this review is that despite the majority of patients being affected 
by AE’s grade 1-2, – and 40-50% of all patients being affected by grade 3 AEs for all of the olaparib 
monotherapy trials in this review, the drug was generally well tolerated causing mainly mild toxicities such as 
nausea, vomiting, fatigue, headache, cough, and a low incidence of myelosuppression.  No secondary 
malignancies were seen as a consequence of taking the drug in any trial.   The toxicities did not differ based on 
germline BRCAm status of those patients except for in a long term safety study (28) where BRCA2m patients 
had 100% CR (but this is only three3 patients so could be due to chance).  
In combination, olaparib seems to improve the therapeutic responses of patients with different cancers to 
platinum (6, 31), although toxicities of these drugs were also increased.  Olaparib seems to enhance the anti-
tumour activity of platinum chemotherapies.  The combination of olaparib with platinum appears a promising 
approach to increase efficacy and warrants further investigation in the future.  
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4. Discussion 
This is the first systematic review looking at the effectiveness of olaparib in BC patients with BRCAm, and 
there are several themes arising from the research into these trials,  – as well as several limitations.   All the 
studies in this SR used quantitative research designs, and all were examining olaparib’s effectiveness in patients 
with BRCAm and associated cancers, measured by objective response rates and adverse effects.  This SR 
focusses on the results for patients with BC. 
 
4.1 Interpretation of Results and Limitations of this Review. 
Despite the author abiding by a strict standard process in order to write this SR as objectively as possible, there 
will always be a difference in interpretation between Kmet et al (23), CASP and hierarchy of evidence.   Of 
particular note for this SR, is that the Kmet et al. (23) method may be flawed as all except one of the trials were 
non-randomised - so for most papers there were irrelevant questions in the Kmet et al. (23) score sheet.   
5 If interventional and random allocation was possible, was it described? NA 
6 If interventional and blinding of investigators was possible, was it reported? NA 
7 If interventional and blinding of subjects was possible, was it reported? NA 
So quality guidelines such as Kmet et al. (23) can be inconsistent in how they rate quality of evidence because 
scoring in this instance means that what are effectively poorer study designs of the RCTs in this review (non-
randomised and open label, small sample sizes) can score as highly as a large sample size fully blinded RCTs 
using Kmet et al.’s (23) method.   
Trial designs in the studies included here  are very heterogeneous with all except one being phase 1 or 2, 
meaning current research in this area is still in it’s infancy and, although two other phase 3 trials are currently 
ongoing, no results are yet available.    Treatment and dosages are not always the same in all studies, and even 
within the same study dosages can be suspended, reduced, increased, or given intermittently.   In dose finding 
trials there were reports of fluctuation in dosage and duration of therapies, with patients switching between 
dosages.   
Despite the heterogeneity of the study designs, the studies did use recognised and established methods for 
conducting the intervention, data collection and analysis, providing valid and reliable results, .   Sso although the 
numbers of patients in the studies are small, and there are only few studies to date, these results can be 
compared and an overview of the body of evidence can be assessed (40).   
Robson et al.’s (30) OlympiAD Trial is the first and only trial in this SR to be randomised.  This trial was 
designed to compare the efficacy and safety of olaparib with the efficacy and safety of a standard therapy of the 
physicians’ choice (TPC) among BC BRCAm patients. Randomisation was stratified according to previous use 
of chemotherapy, hormone receptor status, and previous use of platinum-based therapy. 302 patients were 
randomised 2:1 to olaparib (205 patients) or a chemotherapy of the physician’s choice (97 patients), consisting 
of either capecitabine, vinorelbine or eribulin, although the ideal comparator would have been carboplatin.  
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Future trials should have multiple arms, including platinum arms and a placebo control.  It is of interest to note 
that the ongoing OlympiA study has randomised patients with BRCAm to olaparib or placebo for 12 months, 
after completing surgery and chemotherapy (NCT02032823), but these patients are surviving a long time so the 
end point for this study has not yet been reached, so we wait to see these results when they are available.   
It is important that the demographics of patients at baseline is similar (53).  Patient demographics in all arms 
were similar in all trials, except for the unavoidable differences in individuals’ prior treatment regimes.  Some 
patients were more than three times more heavily treated than others.     All the studies except Robson et al. (30) 
and Gelmon et al. (32) had patients with a median of 3 prior chemotherapies. Robson et al.’s (2017) patients had 
a maximum of two2 prior treatments and Gelmon et al.’s (32) patients were much more heavily pre-treated with 
a median of 4.6 chemotherapies.     
In particular, when reading Van der Noll et al.’s (28) data for this long term safety study, it is important that 
baseline characteristics are taken into account as most patients had already shown anti-tumour response during 
previous combination study (19 out of 21 had benefit, one1 had PD and one1 had a non-evaluable response).   
There is also potential selection bias over time, as only patients that tolerated the treatment actually remained on 
study, however none of the patients that went off study did so because of AEs.  The Berger-Exner test detects 
selection bias but has not been widely utilized in practice (54).   One reason for the non-use of this test may be a 
lack of information regarding its accuracy but Michenautsch et al. (54) concluded that the Berger-Exner test is 
generally accurate for identifying selection bias so this could be utilised to avoid the same potential bias in 
future long term safety studies. 
RCTs where baseline characteristics of patients in each are balanced (which all of these trials did achieve) can 
ensure high levels of internal validity (53).  However, despite establishing that everything that could be done to 
ensure baseline characteristics are as similar as they could be, it must be remembered that none of the studies in 
this SR used a randomised double blinded method in their experimental design, so the risk of  bias must always 
be considered, and this compromises their external validity..    
Small sample sizes are also a limitation of the papers in this SR and all results from studies with small sample 
sizes should be considered with caution.  One of the 3three patients with BRCAm BC in Fong et al.’s (22) trial 
had a CR lasting more than 60 weeks on olaparib 200 mg twice daily, one had SD, but one left the trial. Of the 
26 patients in Gelmon et al.s (32) BC cohort, 11  had BRCAm (although this changed at interim analysis to 10 
as a result of baseline BRCAm testing which found one BRCAm BC patient actually did not have BRCAm, and 
so switched cohort).    The poor sensitivity of BC patients in Gelmon et al.s (32) trial could simply be due to 
chance because of the very small sample size (10 patients) in this study.  Consistent with many of the trials in 
this review, the cohort numbers in Van der Noll et al.s (28) safety study are very small which can lead to bias 
(21, 39, 40). 
A much larger study, so potentially one with greater powerand therefore with more valid reliable results (17, 
38),  by Kaufman et al. (33), published results of a single arm, non-randomised phase 2  trial with 298 patients 
with recurrent BRCAm cancers,  to discover the efficacy and safety of olaparib as a monotherapy in platinum 
resistant OC, heavily pre-treated BC, pancreatic cancer and prostate cancer.  For all patients, ORR was 26.2%, 
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but only 12.9% for BC patients,  – which is low when compared to Tutt et al.s (29) 41% for same BRCAm 
breast cancer patients.   This inconsistency could be explained by the more heavily pre-treated nature of 
Kaufman et al.s (33) patients, but it could also be a more precise accurate result due to the larger sample size. 
It is important to consider timescale and dosing (17) as well as patient drop-out (21) in studies using 
experimental designs.  All trials gave treatment cycles of three3 or four 4 weeks initially, and ran for at least 
six6 cycles (24 weeks).   Not all patients finished six 6 cycles (only 12% in Gelmon et al.s (32) heavily pre-
treated population), but in some cases, patients were still on trial at data cut off (32, 33) with some surviving 
over three3 years (28, 31). Median duration of treatment in BC patients ranged from 56 days (32) heavily pre-
treated population) to (33) days for combination with cisplatin (31).  Additionally it seems that the higher dose 
of olaparib is tolerable over a long time, as Tutt et al.’s (29) patients, treatment exposure ranged from 11 weeks 
in cohort 2 (taking 100mg BiD) to 163 weeks in cohort 1 (taking 400mg BiD).    
Although results are highly variable, it is interesting to note that those patients who survived the longest (over 
3.5 years) were on maintenance therapy after receiving combination therapy.  For those patients who continued 
on olaparib monotherapy after a combination therapy (28) the median treatment time of olaparib monotherapy 
was 52 weeks,  - with a range of 7 weeks to 183 weeks.   It is important for future studies to include long term 
follow up assessments in order to realise the sustainability of olaparib so that both the short-term and the long-
term outcomes of olaparib can be determined (35).   
In Gelmon et al.’s (32) trial three participants results were not confirmed as OR because of absence of 
confirmation at their next visit (three3 BC patients (two 2 BRCAm and one wt).  Given the small numbers in the 
BC BRCAm cohort in this trial (10 patients), had the results of these 3three BC patients been confirmed and 
included in the results, the data would have looked very different,  – and consistent with findings of other 
studies in this review.   This study design is certainly something that could be looked at again with larger sample 
sizes in order to provide more reliable results.  
Fong et al. (22)) also had one BRCAm patient who dropped out with no given reason after one week so no ORR 
was recorded. Further details on this patient would have been useful as they may have experienced an acute 
exacerbation of their illness, or AE to treatment.  Due to lack of information given (22), it was not possible to 
ascertain why this participant dropped out.  This information is crucial because this patient may have been 
different to the other BRCAm patients in the study (39) but these were early days before BRCAm benefit in 
humans was only beginning to be noticed or acted upon (22). There will always be patient drop-out in RCTs, 
especially in females diagnosed with an aggressive cancer affected by strong emotional involvement (55), 
therefore measures should be taken (such as counselling and better communication between researchers and 
participants) to minimise drop-out rates in future, and account for missing data, in order for the findings to be 
valid and generalisable.     
In Kaufman et al.’s study (33), BC and OC patients were moved between cohorts after centrally validated 
BRCAm testing was performed.  Like Balmana et al. (31), Kaufman et al.’s (33) trial has a weakness in that no 
central validation of mutation status was done before enrolment.  The authors of that study believe feel that the 
chance of miss-classification was low, however several patients were moved from one cohort to the other in 
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Gelmon et al.’s (32) trial after BRCA status was subsequently confirmed by Myriad central laboratory, meaning 
that – so this may be an optimistic view, and therefore further trials are warranted where patients BRCAm status 
is centrally validated prior to a study commencing.     
A point of interest resulting from one trial (31) – of those patients who continued single agent olaparib 
monotherapy after the end of the combination trial – is that SD (>1 year) occurred in five breast cancer patients.  
Also, of all ALL patients on the trial with various cancers, two had responses lasting for over three years, but  
Balmana et al. fail to disclose whether these were BC or OC patients.  
Interestingly, Van der Noll et al.’s (28) long term safety study showed reduction of severity and frequency of 
AEs over time.   The most common AE was bone marrow suppression,  – highest at baseline, suggesting a 
possible carry over from the combination study with chemotherapy.  The only haematological AE that persisted 
was anaemia, warranting further investigation of olaparib’s role in anaemia, but encouragingly for olaparib 
therapy, no patients had to omit or discontinue due to AEs. One specific weakness of Van der Noll et al.’s (28)  
study is that there appears to be a discrepancy in the text versus the table.  The authors say in the text that in 
total 8 out of 16 (50%) patients with known BRCA mutations had to come off study due to PD.  Whereas in 
table 4 (in the original text), it shows only one1 patient (8%) having PD.  One1 patient would be more consistent 
with previous and subsequent data for olaparib monotherapy.  There is also a subsequent error in the text, 
referring to the same 8 patients - there were eight patients with BRCA mutation who did show disease 
progression.   The authors have declined to comment despite contacting them several times 
Robson et al.’s (30) trial had comparator arms, which showed more serious AEs occurring more often in the 
TPC cohort.  Grade ≥3 adverse events rate was 36.6% in the olaparib arm and 50.5% in the TPC arm. In 
addition, 4.9% in the olaparib arm discontinued the study because of AEs versus 7.7% in the TPC arm. The 
median treatment duration was more than double in the olaparib arm (8.2 months) than in the TPC arm (3.4 
months).  Interestingly, the most common grade 3 or worse AE’s were caused by anaemia (16·1% in the 
olaparib group vs 4·4% in the TPC group) again raising questions about olaparib’s role in anaemia (which is 
beyond the scope of this SR but worthy of future investigation).   
Despite the apparent success of olaparib monotherapy, combination studies with cisplatin found hematologic 
toxicity too great, and the tolerable schemas required decreasing the standard doses of platinum and were 
limited by dose limiting toxicities (DLTs) (31).  This increase in myelosuppression could be attributed to an 
increase in the sensitivity of rapidly dividing cells to the toxic effects of platinum by olaparib.   A schema of 
intermittent olaparib (50mg BiD, days 1-5) with cisplatin 60mg / m2 was deemed tolerable for further 
development, and this should be explored in the future.  Although not a trial appraised in this review due to its 
focus on biomarker analysis, it is noteworthy here to compare the results of Lee et al.’s (6)2014 
carboplatin/olaparib combination therapy trial,  – which reported 87.5% ORR (table 3.2).  This is the most 
impressive ORR to olaparib in BRCAm cancers found during the research for this SR, and further investigation 
with different combinations of olaparib/platinum is needed in order to achieve anti-tumour efficacy with well 
tolerable regimens, which could greatly improve prognosis and disease outcomes.  Interestingly, Lee et al.’s 
study (6) with carboplatin/olaparib combination therapy reported less frequent AEs, but this could be because a 
tolerable dose was found more quickly.   
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All studies except (22, 28, 33) state that patients had provided written informed consent.  Although there is no 
mention of ethical considerations in one study (28), this is a long term safety study following on from a phase 1 
trial, so approval may have been sought previously for the phase 1 stage.   All studies had been approved by 
review boards and ethics committees for each trial centre, and done in accordance with the recognised Good 
Clinical Practice guidelines and the declaration of Helsinki, which shows that each study has considered and 
addressed the wider ethical concerns. An additional strength of three studies (29, 30, 31), is thatare they are the 
only papers to state that they abide by the sponsors policy on bioethics (48).  However, without written consent 
from each patient, there remains concerns about whether participant’s autonomy, confidentiality, anonymity and 
personal safety have been considered, and we cannot know if that the authors have ensured their patients 
understood what the trial was, or agreed to take part (17, 21, 38, 39).   
Another ethical consideration, given the apparent success of olaparib as a monotherapy, is a potential limitation 
for future RCTs.   Giving olaparib to one cohort whilst giving standard (believed to be inferior) alternative 
therapy or placebo to another cohort can be thought unethical (56).  For example, a non-randomised study 
suggested that multivitamin supplementation (which included folic acid) during pregnancy could prevent neural 
tube defects in developing embryos (57).  Despite the study being deemed flawed (56), ethics committees 
believed it was unethical to deprive patients of this potentially beneficial treatment.  It appears unlikely that this 
currently applies to Whether we are there for olaparib, due to  remains to be seen due to the heterogeneous 
nature of the results so far, but it gives another reason to look forward to the results of the randomised double 
blinded phase 3 RCT results due to be released later this year (OlympiA and neo-Olympia).  
All RCTs in this SR reported a combination of multiple single endpoints (CR, PR, PFS, PD) and all endpoints, 
primary or secondary, should be identified and completely defined (39), which they were.  Robson et al.’s (30) 
017) trial primary end point was PFS, but the authors did also report OS where possible.  At data cut off (– 
December 9, 2016)  – 36 patients were still receiving olaparib and three were still receiving standard therapy.  It 
would be interesting to know whether these patients are still alive and if not, what the OS was.  However, OS 
results could be unreliable because after first disease progression, patients in TPC group received treatment with 
PARPi, platinum and other chemotherapy while still receiving the assigned treatment for this trial 
(supplementary appendix of Robson et al. 2017 (30)).  Additionally, Robson et al.’s (30) trial is the first trial to 
measure time to second progression and further analysis should be done in future for PFS2, and even PFS3, as it 
could be hypothesised that olaparib as a maintenance therapy extends the period of time in between 
chemotherapy treatments, which is better for patients from a toxicity point of view.  
Endpoints are equally important to patients but no trials documented patient preference, or whether patients 
weigh importance of each endpoint differently (58). Measuring QoL is important because it improves 
understanding of a patient's problems by enabling communication between physician and patient (59). Robson 
et al.’s (30) OlympiAD trial does measure quality of life (QoL) alongside clinical effectiveness.  Despite being 
outside the scope of this review, it is interesting to note that the QoL data showed a meaningful improvement in 
health-related quality- of-life measures in the olaparib arm.   Briefly, the European Organization for Research 
and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 has is a questionnaire with 100 
points, developed to assess the quality of life of cancer patients (60).  In the OlympiAD trial (30) a drop of 10 
point or more was considered a clinically meaningful decrease, which was not reached in olaparib group and 
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took 15.3 months in standard therapy group.   The onset of response was similar for both groups,  – which is 
important when deciding which therapy to give patients in future, especially given the higher ORs and lesion 
shrinkage rates with olaparib versus standard therapy (30).   
At the time of writing, the complete OS data  is not available due to the authors report that it is claiming it is not 
yet mature, but a pre-planned interim analysis revealed no difference between olaparib and TPC cohorts (19.3 vs 
19.6 months, respectively), likely because of the high degree of cross‐over during treatments for PD as 
mentioned previously. However, if olaparib does extend PFS, but does not extend OS, then it will become 
important in future trials to assess patient’s’ QoL during this time,  – in order to assess additional benefit of 
olaparib to patient’s lives, rather than just clinical effectiveness.  
 
4.2 Implications Regarding Hierarchy of Evidence and Clinical Effectiveness 
Most quantitative investigators argue that RCTs should be central to evidence- based decision making practice, 
since in terms of clinical effectiveness, it is necessary to know the cause and effect relationship between and 
intervention and the results, based on valid and reliable outcomes (61, 62).    Traditionally RCTs are a way of 
assessing the effectiveness of different ‘treatments to find out which one works best relative to others (39) and 
are considered to be the ‘gold standard’ in this regard for judging whether a treatment does more good than 
harm (63).   
However, as we have seen, the trials RCTs assessed here have provided several limitations:  to this SR – low 
number of RCTs, small sample sizes, single arm, non-randomised and unblinded designs, study limitations, 
imprecision and possible reporting bias.  Additionally, there is variation in some methods and results between 
studies, resulting in a lack of statistical meta-analysis, all of which weakens the strength of the evidence 
contained within the RCTs and this SR.  Guyatt et al. (2011) (64), highlights that a high risk of bias can mean 
studies are rated down as a lesser robust quality evidence when compared to the gold standard RCT,  - which 
has been shown to be the case for the studies in this SR.   From a post-positivist stance, Mantzoukas et al. (65) 
discourage an acceptance of RCT as the ‘gold standard’ in some circumstances because they cannot 
accommodate the diversity of patients and real situations faced in daily practice, and therefore the trials included 
in this SR illustrate pragmatism in design and conduct which has allowed scientists to begin evaluating the 
effectiveness of olaparib, but has not yet delivered a conclusive result..   
However, CEBM says that not all SRs of heterogeneous RCTs need cause concern, and not all heterogeneity of 
results is statistically significant. Overall, despite RCTs currently being at the heart of evidence based practice 
(66), the conclusion of this SR suggests that RCTs being near at the summittop , and SRs of RCTs being the 
pinnacle of the ‘hierarchypyramid of evidence’ remains a controversial issue.  At the heart of this conclusion is 
the basis that the development of the RCT is to discover an intervention’s ‘effectiveness’. The function of the 
trialsRCTs in this SR is to determine whether olaparib is clinically effective:  – does it ‘work’?   What are the 
ORRs of olaparib as an autonomous treatment? These studies included in this SR  In this case, the RCTs have a 
clear concept of whether olaparib ‘works’, as the clinical effectiveness is measured, compared and analysed.   
However, tThere are further questions about whether olaparib ‘works’ for the patients, and whether it ‘works’ 
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for the healthcare service which are not answered in six out of seven (all except (30)) of the trials RCTs in this 
review.   
 
 
5. Conclusions  
The aim of a SR is to find, analyse, appraise, and summarise the best available evidence related to a specific 
research question, in order to provide evidence-based answers for practice (67).    
As this review is focussed on clinical effectiveness, results from studies used in this systematic review need the 
show clinical benefit (or not) to the patient, and the response of the tumour/lesion to olaparib treatment.  Results 
will ideally measure OS, PFS, and ORR, which include CR and PR and SD, and possibly the time until disease 
progression or other interventions (such as chemotherapy, surgery or death).  Results also need to show AE 
resulting from the intervention.   
Olaparib (made by Astra Zeneca), an oral PARP inhibitor, is tolerated as a single-agent in continuous doses up 
to 400 mg (Fong et al 2009 (22)). Olaparib has been shown to have promising activity in patients with 
metastatic BC and BRCAm and has been active as monotherapy in tumours with defective HR repair, 
specifically with BRCAm (29, 33). Clinical activity with extended stable disease (SD) or tumour response 
(reduction) has been reported in BRCAm BC and OC (29, 32). Phase 2two studies have confirmed the activity 
of olaparib monotherapy BRCAm patients with advanced BC (29Tutt et al 2010) and those with OC (22). 
Olaparib has been successful at inducing CR, PR and SD in BRCAm BC patients.  Responses were often 
sustained, even in patients who were heavily pre-treated, making these results significant even in the absence of 
a comparator arms in most studies.  
In summary, olaparib as a targeted therapy for BC with BRCAm could potentially shift the paradigm of treating 
BRCAm BC away from chemotherapy towards targeting individual tumour biology. However, genetic 
complexity and ORR heterogeneity is currently a major limitation to the success of individually targeted 
therapy, and further research is needed. 
 
5.1 Strength of Conclusions  
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) is an approach used to 
assist a transparent approach to grading quality of evidence, and in line with GRADE criteria (table 4), the 
quality of evidence in all of these studies would be graded as low quality because further research is very likely 
to have an important impact on our confidence in the estimate of effect (68; – table 5 below). Only one (30) had 
a comparatively very large sample size (302 patients with BC and BRCAm) and used comparator arms with 
randomisation, so this trial could be graded as ‘moderate quality’ because further research is likely to have an 
important impact on our confidence in the estimate of effect and may change the estimate (68;  – table 4 below)., 
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Overall, the seven studies together as a body of evidence would be considered ‘low quality’ according to the 
GRADE criteria shown in table 4. 
 
Table 4 -– GRADE Qquality of evidence and definitions 
 
 High quality— Further research is very unlikely to change our confidence in the estimate of effect 
 Moderate quality— Further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate 
 Low quality— Further research is very likely to have an important impact on our confidence in the 
estimate of effect and is likely to change the estimate 
 Very low quality— Any estimate of effect is very uncertain 
 
5.2 Limitations 
There is also the matter of subjectivity to consider.  Despite this being a quantitative SR with quantitative 
methodology and methods, there is still room for personal subjectivity from the point of view of the reader.  Are 
the papers in this review the ones someone else would rank as best answering the question: ‘What is the current 
effectiveness of olaparib for breast cancer patients with BRCAm?’ – Are the methods and methodology used in 
this review ones that the reader agrees with or not.  However, if GRADE is used consistently, then the 
advantages of simplicity and clarity outweigh these limitations.  
Quality of evidence is subjective and judgments about evidence and recommendations in healthcare are 
complex, however despite the limitations regarding the quality of the evidence, the authors haves been clear 
about how conclusions were drawn about the quality of evidence, and how it was synthesised in this review, 
explaining Kmet et al. (23), CASP and GRADE measurement and scoring techniques, as well as using the 
CONSORT guidelines for reporting of clinical trials in order to assess the quality of the RCTs in this SR. 
Although poor quality studies may lead to biased outcomes (69), and the conclusion of this review indicates the 
evidence to date is low quality,  due to uncertainty of future larger studies research results, the researchers of the 
primary evidence included in this SRresearchers were rigorous in their methods – and they reported their work 
in enough detail for others to assess its quality (70).   Given the evidence to date, the outcome of the seven 
studies in this SR does suggest that the desirable effects of olaparib do outweigh the undesirable adverse effects.  
 
5.3 Recommendations for Future Research   
Questions remain about how best to use olaparib – either in combination with chemotherapy or as maintenance 
alone.  Combination therapies with olaparib in this SR are extremely limited in number and the selection of the 
best therapeutic partner is as yet unknown.   Such limitations and uncertainties increase the uncertainty of these 
combination therapies and more studies ofin combination therapy are needed.  A randomised six arm study 
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(including a placebo) could help to define whether an olaparib monotherapy, or olaparib/cisplatin combination 
therapy, or olaparib/carboplatin combination, improves clinical efficacy versus either platinum agent alone.   
Additionally, combination trials with other chemotherapy, radiation, immunotherapy and molecular targeted 
agents should also being explored.    
It would also be very interesting to test whether a sequential treatment of olaparib monotherapy, after positive 
response with a platinum-based therapy would improve the duration of response compared with 
olaparib/platinum combination therapy.  Responses were observed with combination therapy, followed by 
durable responses to olaparib monotherapy in patients with BC.  These finding suggest that olaparib might be a 
promising maintenance treatment following monotherapy or combination chemotherapy, which is a strategy that 
should be tested in future studies.   
Olaparib/chemotherapy combinations to date indicate platinum therapies might have overlapping mechanisms of 
actions to olaparib and might therefore be limited by shared mechanism of resistance. This warrants further 
exploration, beyond our current knowledge that BRCAm tumours are sensitive to platinum for the same reason 
they are sensitive to olaparib.  Not all BRCAm tumours in this SR responded to olaparib, and some non-BRCA 
tumours did respond to olaparib despite, in some cases, prior platinum treatment.    This means there is a 
possibility that crossover of mechanism may not be as clear as we think, and is an area of research that needs 
further investigation. 
Currently BRCAm is the most reliable biomarker used to select patients for olaparib therapy, whether in 
combination or not, but as we have seen, not all BRCAm tumours responded to olaparib, and some non-BRCA 
tumours did respond to olaparib,  – suggesting synthetic lethal interaction with olaparib may be exploited 
beyond BRCAm.  New biomarkers to predict response to olaparib is an area requiring more research in order to 
identify all patients who might benefit from olaparib. It is clear that if olaparib is to expand into a BRCAwt 
population, a greater understanding of mechanism of crossover of resistance is required and robust indicator 
tests outside of prior platinum response are needed.  
While it is clear that olaparib has beneficial activity in BC, the timing of its use remains in question, whether as 
monotherapy, in combination therapy or as a maintenance therapy.  Given the success of olaparib in advanced 
metastatic BRCAm breast cancer, future trials are also needed to study the role of olaparib in early stage 
disease.  
Quality of life (QoL) is something to consider for future trials.  Olaparib did have lower toxicities and improved 
QoL compared to other therapies. Trials RCTs so far have not demonstrated increased OS, in spite of PFS 
benefit. However, the future gold standard for assessment of efficacy of olaparib should be a clinically 
meaningful improvement in OS and quality of life (QOL), so future trials must include these in their measured 
outcomes.  
The application of olaparib, (and other PARPi) is an ideal example of the concept of personalised cancer care:  – 
identifying molecular and or genetic differences and exploiting them to ultimately improve patient therapy and 
care. Studies in this SR looking at effectiveness show olaparib as an effective, tolerable therapy that could be 
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expanded to other patients groups with further research. However, going  moving forward, we have to further 
decide whether this is both feasible and appropriate with regard to patient care.     
Firstly there is the matter of price. Olaparib is an expensive drug costing $12,155 per month (71).   To put this 
into perspective, consider Robson et al.s (30) 2.8 month PFS benefit which  - this amounts to $100,000 per 
patient.  Despite the QoL results, we must consider whether the tax-payer is ready to spend this kind of money 
per person, for a relatively rare type of BC, when there are so many more people with other BCs, and other 
chronic diseases (diabetes and heart disease for example) that impact on our health as a society.  This may not 
be such an acute consideration in insurance-based health care systems, but will be central to decision making in 
the UK NHS.   
Secondly, genetic testing comes with its own set of problems. Despite genetic testing becoming more 
affordable, clinical support services would need more funding to cover other services such as genetic 
counselling for patients and their relatives, and communication with patients and their families about results and 
what it means for everyone who could be affected.    Further research to identify patients and tumour groups that 
may derive therapeutic benefit from olaparib is required, and research into predictive biomarkers will be crucial 
to help with that stratification in the future.     
These are important factors to consider in evidence based practice and making the decision of whether to 
implement olaparib therapy in a clinical setting (35). 
Bryant & Benton ((72) suggest that in our quest for the very best healthcare, we must constantly strive to use 
evidence based practice and healthcare practitioners should use the research to challenge, improve, or evaluate 
practice (73).    
Overall, the purpose of this SR is to answer the question ‘What is the current effectiveness of olaparib for 
patients with breast cancer and a BRCA mutation?’  The answer is that - olaparib is an active PARPi that has 
shown significant positive clinical effects results in patients with recurrent BC and BRCAm, and compared with 
single-agent chemotherapy, olaparib monotherapy improves clinical benefit and reduces AE in patients with BC 
and BRCAm.    
However, much larger, longer term studies to investigate the different treatment effects of olaparib among sub- 
groups are needed, particularly for patients with prior use of platinum therapy, as would a direct comparison 
study to determine the relative efficacy of olaparib versus platinum therapies. Development of combination 
regimes is also needed to find the most effective schema with lowest AEs.  More long term safety studies and 
follow ups after RCTs are required to establish long term toxicities and risk of secondary malignancies. Future 
trials must include OS and QoL in their measured outcomes. In addition, as shown in this chapter, there are 
several further areas where more research is needed in order to realise the full potential effectiveness of 
olaparib.   
However, since 2009, olaparib has been investigated in BC with the most compelling results found in the subset 
of patients who harbour BRCAm.  Based upon this fact, olaparib should be regarded as a clinically effective 
potential addition in the fight against BC for patients with BRCAm.  
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GLOSSARY OF TERMS AND ABBREVIATIONS 
 
AE   Adverse event/effect 
ASCO   American Society of Clinical Oncology  
AZ   Astra Zeneca 
BiD   twice a day 
BRCA    Breast cancer gene 
BRCAm   mutant breast cancer gene 
BRCAwt  wild-type breast cancer gene 
BC    Breast cancer 
CASP   Critical Appraisal Skills Programme 
CEBM   The Oxford Centre for Evidence-based Medicine  
CINAHL  Cumulative Index to Nursing and Allied Health Literature  
COCHRANE  The Cochrane library 
CR   Complete response 
CRD   Centre for Reviews and Dissemination 
CTCAE   Common Terminology Criteria for Adverse Events  
DLT   Dose limiting toxicity 
DNA   Deoxyribonucleic acid 
ECOG   Eastern Cooperative Oncology Group 
EMA   European Medicines Agency  
EORTC   European Organization for Research and Treatment of Cancer  
FDA   Food and drug administration (USA government dept.) 
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GRADE   The Grading of Recommendations Assessment, Development and Evaluation 
Grey material  unpublished material or evidence 
JBI   Joanna Briggs Institute 
MTD   Maximum tolerated dose 
NHS   National Health Service 
NICE   National Institute for Health and Care Excellence  
OC   Ovarian Cancer 
OR(R)   Objective response (rate) 
OS   Overall survival 
PR   Partial response 
PD   Progressive disease 
PFS   Progression free survival 
PARPi   Poly (ADP-ribose) polymerase inhibitors 
PICO   population, intervention, comparative intervention, outcome 
PROSPERO   an international database of prospective SRs 
PRIMO   University of Plymouth online library 
PRISMA  Preferred reporting items for systematic reviews and meta-analyses 
PRISMA-P  Preferred reporting items for systematic reviews and meta-analyses for protocols 
QoL   Quality of life 
RCT   Randomised clinical trial 
RECIST   Response Evaluation Criteria in Solid Tumours 
SD   Stable disease 
SR   Systematic review 
TNBC   Triple negative breast cancer 
TPC   Therapy of physician’s choice 
WHO   World Health Organisation  
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